 |
Outsourcing the data centre to a carrier neutral data centre operator in Europe
Find out how to drive down the cost of your IT environment--and drive up the reliability and quality of your service--by outsourcing your data center.
Sponsored by: Telecity Group
Date: October 2009 |
|
- Show only
- White Papers
- Webcasts
- Case Studies
- Show all content
- Showing items 41-80 of 670
- « Previous 40 | Next 40 »
 |
Pharmaceuticals
This paper briefs about U.K pharmaceutical industry. There are 350 pharmaceutical manufacturers operating in U.K. The output of the industry has increased on average by...
Company: Barclays
Date: June 2002 |
Barclays |
|
New Data From VELCADE (Bortezomib) for Injection Crest Study Indicate Responses in Patients With Relapsed Multiple Myeloma
In this article Millennium Pharmaceuticals, Inc. elaborates and gives information about their final results of the phase II CREST study (previously known as 024) for...
Company: Millennium Pharmaceuticals
Date: December 2002 |
Millennium Pharmaceuticals |
|
Integrilin (Eptifibatide) Injection: For Intravenous Administration
In this article Millennium is investigating the potential role of INTEGRILIN beyond its currently approved indications. INTEGRILIN is approved for marketing in the U.S. for...
Company: Millennium Pharmaceuticals
Date: July 2004 |
Millennium Pharmaceuticals |
|
Millennium Submits New Drug Application for VELCADE (Bortezomib) for Injection
In this article Millennium Pharmaceuticals, Inc. informs that it has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for...
Company: Millennium Pharmaceuticals
Date: January 2003 |
Millennium Pharmaceuticals |
|
Millennium Initiates Phase I Clinical Trial of MLN518 in Acute Myeloid Leukemia (AML)
In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I clinical trial of MLN518 in patients with Acute Myeloid Leukemia (AML). This...
Company: Millennium Pharmaceuticals
Date: May 2002 |
Millennium Pharmaceuticals |
| More Search Results Below | ||
|
Millennium Discovers Markers Associated With Chemotherapy Response in Breast Cancer Patients
This article elaborates and gives information about breast cancer patients. Millennium Pharmaceuticals discusses the results from a preliminary, prospective study seeking to identify novel genetic...
Company: Millennium Pharmaceuticals
Date: December 2002 |
Millennium Pharmaceuticals |
|
Millennium Announces Assignment of Medicare Code for Velcade (Bortezomib) for Injection
In this article Millennium Pharmaceuticals, Inc. informs that the Center for Medicare and Medicaid Services (CMS) has qualified VELCADE for pass-through status and assigned it...
Company: Millennium Pharmaceuticals
Date: September 2003 |
Millennium Pharmaceuticals |
|
Final Phase II Data Presented From the VELCADE (Bortezomib) for Injection SUMMIT Trial in Patients With Advanced Stage Multiple Myeloma
In this article Millennium Pharmaceuticals, Inc. discusses their final results from the phase II SUMMIT trial (previously known as 025) for its investigational cancer drug...
Company: Millennium Pharmaceuticals
Date: December 2002 |
Millennium Pharmaceuticals |
|
Millennium Initiates Phase II Clinical Trial With MLN1202 in Patients With Rheumatoid Arthritis
In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a multicenter phase II clinical trial of MLN1202 in approximately 30 patients with rheumatoid arthritis....
Company: Millennium Pharmaceuticals
Date: October 2003 |
Millennium Pharmaceuticals |
|
VELCADE (Bortezomib) for Injection
In this article Millennium Pharmaceuticals, Inc. informs about the approval from the U.S. Food and Drug Administration (FDA) to market VELCADE for the treatment of...
Company: Millennium Pharmaceuticals
Date: May 2003 |
Millennium Pharmaceuticals |
|
New Clinical Trial Data Showed the Addition of INTEGRILIN (Eptifibatide) Injection Achieved Superior Platelet Inhibition and Less Heart Muscle Damage When Compared to a Commonly Used Antiplatelet Regimen Alone
In this article Millennium Pharmaceuticals, Inc. discusses the CLEAR Platelets (Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets) trial, the addition of INTEGRILIN,...
Company: Millennium Pharmaceuticals
Date: November 2004 |
Millennium Pharmaceuticals |
|
New Data Reveal Clinical Differences Between INTEGRILIN (Eptifibatide) Injection and Bivalirudin
In this article Millennium Pharmaceuticals, Inc. discusses the results of the PROTECT trial, which was designed to compare the glycoprotein (GP) IIb-IIIa inhibitor INTEGRILIN with...
Company: Millennium Pharmaceuticals
Date: November 2004 |
Millennium Pharmaceuticals |
|
FDA Grants VELCADE (Bortezomib) for Injection Fast Track Status for Relapsed and Refractory Mantle Cell Lymphoma In this article Millennium Pharmaceuticals, Inc. informs that the Food and Drug Administration (FDA) has granted VELCADE fast track designation for relapsed and refractory mantle... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Files Supplemental New Drug Application for VELCADE (bortezomib) for Injection for the Treatment of Patients With Second-Line Multiple Myeloma In this article Millennium Pharmaceuticals, Inc. discusses the submission of the Company's supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA)... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Announces Findings From a Phase I Clinical Trial of MLN2704 in Progressive, Metastatic Hormone-Refractory Prostate Cancer In this article Millennium Pharmaceuticals, Inc. discusses their preliminary results from a phase I clinical trial of MLN2704 in patients with progressive metastatic hormone- refractory... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
VELCADE (Bortezomib) for Injection Shows Promising Activity in Two Phase II Studies of Patients With Previously Untreated Multiple Myeloma In this article Millennium Pharmaceuticals, Inc. displays the encouraging data from two ongoing phases II investigator-sponsored clinical trials examining the potential role of VELCADE in... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
VELCADE (Bortezomib) for Injection Data Show a Significant Improvement in Survival in Patients With Relapsed Multiple Myeloma
In this article Millennium Pharmaceuticals, Inc. discusses the results from its phase III confirmatory APEX trial which show a statistically significant improvement in survival in...
Company: Millennium Pharmaceuticals
Date: June 2004 |
Millennium Pharmaceuticals |
|
Millennium and Schering-Plough Initiate Clinical Trial With INTEGRILIN (Eptifibatide) Injection in Early Use Acute Coronary Syndrome Setting In this article Millennium Pharmaceuticals, Inc. and Schering-Plough Corporation discusses the initiation of a multicenter phase IIIb clinical trial to evaluate the benefit of INTEGRILIN... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Announces VELCADE (Bortezomib) for Injection has Significantly Extended Survival in Phase III (APEX) Trial of Patients With Relapsed Multiple Myeloma In this article Millennium Pharmaceuticals, Inc. discuses their final survival endpoint analysis in the phase III confirmatory APEX study comparing patients receiving VELCADE to those... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Initiates Phase II Clinical Trial With VELCADE and Rituximab in Patients With Indolent Non-Hodgkin's Lymphoma
In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a multicenter phase II clinical trial of VELCADE (Bortezomib) for injection in combination with rituximab...
Company: Millennium Pharmaceuticals
Date: May 2004 |
Millennium Pharmaceuticals |
|
Independent Committee Recommends Early End to Confirmatory Phase III VELCADE Trial Based on Achieving Statistically Significant Improvement in Primary Endpoint In this article, Millennium Pharmaceuticals, Inc informs that the company, based on the recommendation of an independent data monitoring committee and the notification of regulatory... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Early Research Advances Field of Proteasome Biology In this article, Millennium Pharmaceuticals, releases findings which implicate the proteasome pathway in tuberculosis and extend the understanding of the pathway in stroke, advancing the... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Preliminary Study Results of VELCADE (Bortezomib) for Injection Combined With Thalidomide Demonstrated Anti-Tumor Activity in Patients With Advanced Multiple Myeloma In this article, Millennium Pharmaceuticals, Inc. gives promising preliminary phase I/II study results from an investigator initiated study (IIS) examining the use of VELCADE in... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
New Phase II Findings Support Potential Role of VELCADE (Bortezomib) for Injection in Patients With Non-Hodgkin's Lymphoma In this article Millennium Pharmaceuticals, Inc gives the results of two clinical trials with VELCADE in patients with non-Hodgkin's lymphoma (NHL), in which early signs... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Preliminary Phase II Results With VELCADE (Bortezomib) for Injection Demonstrated Activity in Patients With Previously Untreated Multiple Myeloma In this article Millennium Pharmaceuticals, Inc. discusses the encouraging preliminary phase II study results from an investigator-initiated study (IIS) examining the use of VELCADE for... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
FDA Grants Millennium Fast Track Status for MLN2704 In this article Millennium Pharmaceuticals, Inc. informs that the U.S. Food and Drug Administration (FDA) have granted its investigational cancer therapy, MLN2704, fast track designation.... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Initiates Phase I/II Clinical Trial of MLN2704 in Patients With Metastatic Androgen-Independent Prostate Cancer Second Clinical Trial With MLN2704
In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I/II multiple ascending-dose clinical trial of MLN2704 in patients with metastatic androgen-independent prostate...
Company: Millennium Pharmaceuticals
Date: October 2003 |
Millennium Pharmaceuticals |
|
Millennium Initiates Phase II Clinical Trial With VELCADE (Bortezomib) for Injection in Patients With Relapsed or Refractory Mantle Cell Lymphoma In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a multicenter phase II clinical trial of VELCADE in patients with relapsed or refractory mantle... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Announces Promising Early Study Results With VELCADE (Bortezomib) for Injection Combined With Doxil in Patients With Advanced Multiple Myeloma In this article Millennium Pharmaceuticals, Inc. discusses the preliminary phase I study results, examining the use of its novel oncology product, VELCADE, in combination with... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Announces Preliminary Phase I and Phase II Findings of VELCADE (Bortezomib) for Injection in Studies of Non-Hodgkin's Lymphoma and Solid Tumors
In this article Millennium Pharmaceuticals, Inc. discusses the results of several clinical trials with its novel oncology product VELCADE, in which early signs of anti-tumor...
Company: Millennium Pharmaceuticals
Date: June 2003 |
Millennium Pharmaceuticals |
|
In Phase II Study, Millennium Investigational Drug MLN02 Produced Significant Improvement in Ulcerative Colitis Remission Rates as Compared to Placebo In this article Millennium Pharmaceuticals, Inc. discusses the results of a phase II trial of its investigational drug MLN02 in patients with ulcerative colitis, which... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Groundbreaking Research Identifies Molecular Pathway Underlying Key Infection-Fighting Mechanism In this article researcher at the University of Massachusetts Medical School (Worcester), Harvard University and Millennium Pharmaceuticals, Inc. reveals the discovery of a new pathway... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Initiates Phase II Clinical Trial With Velcade (Bortezomib) for Injection fn Patients With Advanced Non-Small Cell Lung Cancer In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase II clinical trial of VELCADE in patients with stage IIIb (locally advanced) or... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Initiates Phase II Clinical Trial With VELCADE (Bortezomib) for Injection in Patients With Colorectal Cancer In this article Millennium Pharmaceuticals, Inc. discusses the recent initiation of a phase II clinical trial of VELCADE in patients with colorectal cancer. The randomized,... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Initiates Phase I Clinical Trial of MLN1021, a Novel, Oral Factor Xa Inhibitor In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I clinical trial of MLN1021, an orally administered inhibitor of Factor Xa, a... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Initiates Phase I Clinical Trial of MLN1202 In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I clinical trial of MLN1202. MLN1202, a novel humanized monoclonal antibody that blocks... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Discovers Marker Associated With Chemotherapy Response in Breast Cancer Patients In this article Millennium Pharmaceuticals, Inc. discusses their results from a preliminary, prospective study seeking to identify novel genetic predictors of breast cancer patients' response... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Initiates Phase I Clinical Trial of MLN2704 in Patients With Metastatic Androgen Independent Prostate Cancer In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I clinical trial of MLN2704 (formerly known as MLN591DM1) in patients with metastatic... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
New Data Show Hospital Adherence to Chest Pain Guidelines Reduced Risk of Death by Nearly Half In this article Millennium Pharmaceuticals, Inc., and Schering-Plough Corporation discusses results from an ongoing national quality improvement initiative examining adherence to American College of Cardiology... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Announces Initiation of Phase III Clinical Trial of INTEGRILIN (Eptifibatide) Injection in Heart Attack Patients In this article Millennium Pharmaceuticals, Inc. describes the initiation of a phase III clinical trial of INTEGRILIN in patients experiencing an ST- segment elevation myocardial... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
- Showing items 41-80 of 670
- « Previous 40 | Next 40 »
Submit a Paper
- Get your content listed in our directory! Our members are already finding your competitors' papers here -- shouldn't they find yours, too? It's FREE so click here and submit your white paper, case study, data sheet, research report, or other document today!
